亜鉛フィンガーRan結合タンパク質3(ZRANB3):高度な視点
Paride Pelucchi1, Ettore Mosca1, Nika Tomsič2
1Istituto di Tecnologie Biomediche (ITB), Consiglio Nazionale delle Ricerche (CNR), Via Fratelli Cervi 93, 20054 Milano, Italy.
International journal of molecular sciences
|January 28, 2026
まとめ
ヒトZRANB3タンパク質は、DNA損傷許容およびゲノム安定性に不可欠であり、腫瘍抑制因子として機能します。がんにおける発現変動は予後不良と相関しており、その予後予測の可能性を強調しています。
科学分野:
- 分子生物学
- 遺伝学
- がん研究
背景:
- ヒト亜鉛フィンガーRan結合タンパク質3(ZRANB3)は、DNA損傷許容(DDT)に不可欠です。
- ZRANB3は複製フォーク逆転(RFR)およびp53/Polι経路で機能し、腫瘍抑制因子としての役割を示唆しています。
- 腫瘍におけるZRANB3の調節不全は、不良な臨床転帰と関連しています。
研究 の 目的:
- ZRANB3に関する遺伝子およびタンパク質レベルの文献を包括的にレビューすること。
- がん発生におけるZRANB3の調節を調べること。
- 腫瘍抑制因子および予後バイオマーカーとしてのZRANB3の役割に関するエビデンスを議論すること。
主な方法:
- 遺伝子およびタンパク質データを統合した文献レビュー。
- DNA損傷許容および複製フォークダイナミクスにおけるZRANB3の役割の分析。
- がんにおけるZRANB3の変化(変異、コピー数)の検討。
主要な成果:
- ZRANB3はDNA損傷を防ぎ、フォーク進行を回復させることでゲノム安定性を維持します。
- ZRANB3の発現は腫瘍で頻繁に調節不全となり、予後不良と相関しています。
- ZRANB3 mRNAとp53の発現との相関は、特にp53変異がんにおいて、文脈依存的です。
結論:
- ZRANB3はDNA修復経路に関与する重要な腫瘍抑制因子です。
- 変化したZRANB3は、様々ながんにおいて重要な予後バイオマーカーです。
- DNA合成および代謝におけるZRANB3の機能に関するさらなる研究が推奨されます。
関連する概念動画
Factors Affecting Protein-Drug Binding: Protein-Related Factors
551
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
551
The Equilibrium Binding Constant and Binding Strength
15.0K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
15.0K
Drug Distribution: Plasma Protein Binding
8.8K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
8.8K
Protein-Drug Binding: Determination Methods
648
Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
648
Single-Strand DNA Binding Proteins
16.7K
For successful DNA replication, the unwinding of double-stranded DNA must be accompanied by stabilization and protection of the separated single strands of the DNA. This crucial task is performed by single-strand DNA-binding (SSB) proteins. They bind to the DNA in a sequence-independent manner, which means that the nitrogenous bases of the DNA need not be present in a specific order for binding of SSB proteins to it. The binding of SSB proteins straightens single-stranded DNA (ssDNA) and makes...
16.7K
Protein-Drug Binding: Mechanism and Kinetics
1.8K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
1.8K


